miRpredX 31-3p

Introducing the first positive theranostic test for patients with metastatic colorectal cancer.

The miRpredX 31-3p CE-IVD in vitro diagnostic kit is designed to quantify the expression of the microRNA miR-31-3p in FFPE samples from primary tumors obtained from patients with RAS WT metastatic colorectal cancer (mCRC).

The miRpredX 31-3p test predicts the potential clinical benefits associated with first-line anti-EGFR (epidermal growth factor receptor) therapy compared to anti-VEGF (vascular endothelial growth factor receptor) therapy or when second or further lines of treatment with anti-EGFR therapy is beneficial versus chemotherapy alone for patients with RAS WT mCRC.